

Development Senescence-based Target Drugs for GBM – 2nd Generation Drug of Interstitial Chemotherapy

Shinn-Zong Lin^{1,2,3,4}, Horng-Jyh Harn^{5,6}, Tzyy-Wen Chiou⁷

¹Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan

²Department of Neurosurgery, China Medical University Beigan Hospital, Yunlin, Taiwan

³Department of Neurosurgery, Tainan Municipal An-Nan Hospital-China Medical University, Tainan, Taiwan

⁴Graduate Institute of Immunology, China Medical University, Taichung, Taiwan

⁵Department of Medicine, China Medical University, Taichung, Taiwan

⁶Department of Pathology, China Medical University Hospital, Taichung, ⁷Taiwan TaiwanDepartment of

⁷Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan

Malignant brain tumor is the most fatal and shortest survival time disease. Local recurrence with migrating and invading along with the adjacent tracts of blood vessels and neural fibers is one of the major mechanisms of disease progression. BCNU wafer (Glioblastoma wafer) is currently available as an interstitial chemotherapy for primary and recurrent malignant brain tumor, but this therapy is adopted by neurosurgeons only in small portion of all cases due to the toxic effects of BCNU, which causes brain swelling and poor wound healing. Based on this unmet medical need, a new generation of interstitial controlled releasing drug for treating malignant brain tumor has been developed, named as Cerebraca wafer, in which BCNU is replaced with Cerebraca, a new small molecular drug targeting Nurr77 and ASL-1, thereby causing tumor cell apoptosis and inhibiting tumor invasion and migration. The CMC, formulation, pharmacokinetics, pharmacodynamics, toxicology etc. will be presented at meeting. Cerebraca wafer is firing IND to U.S.A. FDA for clinical trial.